Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 9/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1413660 | 0.86 | CXCR4 (0.48) | MAPTCCR1ALDH1A1DGAT2LMNA | |
| Hydrochloric Acid SCHEMBL4009397 | 0.85 | CXCR4 (0.48) | MAPTCCR1ALDH1A1DGAT2LMNA | |
| SCHEMBL12810342 | 0.78 | ALDH1A1 (0.49) | ALDH1A1DGAT2LMNAHTR6 | |
| Hydrochloric Acid SCHEMBL1413802 | 0.78 | ALDH1A1 (0.48) | ALDH1A1DGAT2LMNAHTR6 | |
| SCHEMBL1413651 | 0.76 | CXCR4 (0.54) | MAPTALDH1A1LMNAHTR6 | |
| SCHEMBL1413723 | 0.76 | CXCR4 (0.49) | MAPTALDH1A1LMNAHTR6 | |
| SCHEMBL1413819 | 0.76 | HTR6 (0.60) | ALDH1A1DGAT2HTR6 | |
| SCHEMBL1413794 | 0.76 | CA1 (0.47) | MAPTHTTDGAT2LMNAHTR6 | |
| SCHEMBL1413828 | 0.76 | HTR6 (0.58) | MAPTALDH1A1LMNAHTR6 | |
| SCHEMBL1413841 | 0.75 | CXCR4 (0.50) | MAPTALDH1A1DGAT2LMNAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | CNR1, CNR2, MAG | MAPT 548/4885CCR1 136/4885KDM4E 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.